MedTrace Logo

Ropivacaine 0,2% Plus Dexamethasone Versus Ropivacaine 0,2% Plus Placebo in Modified Pectoral Block

NCT03700177 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-03-12

No results posted yet for this study

Summary

To find out if dexamethasone used as adjuvant to ropivacaine, a long-lasting local anesthetic, prolongs the duration of modified pectoral nerve block in women undergoing breast surgery.

Conditions

  • Effect of Drugs
  • Breast Pain
  • Anesthesia, Local

Interventions

DRUG

Dexamethasone

modified pectoralis block for breast surgery with ropivacaine combined with dexamethasone 8mg.

DRUG

Placebo

modified pectoralis block for breast surgery with ropivacaine combined with placebo (NaCl 0,9%).

DRUG

Ropivacaine Injection [Naropin]

30ml (=60mg) for modified pectoralis block (thoracic regional fascial plane block)

Sponsors & Collaborators

  • Medical University Innsbruck

    lead OTHER

Principal Investigators

  • Karl Lindner, Prof.Dr. · Department of Anesthesia and Intensive Care

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03700177 on ClinicalTrials.gov